Revisiting coexisting chromosomal abnormalities in <i>NPM1</i>-mutated AML in light of the revised ELN 2022 classification
Linus Angenendt, Christoph Röllig, Pau Montesinos, Farhad Ravandi, Gunnar Juliusson, Christian Récher, Raphaël Itzykson, Zdeněk Ráčil, Andrew H. Wei, Christoph Schliemann
Abstract
Mutations in the nucleophosmin 1 gene (NPM1) occur frequently in acute myeloid leukemia (AML) and are associated with a favorable prognosis. Applying the new 2022 European LeukemiaNet (ELN) classifier, Angenendt et al tested the prognostic significance of the copresence of NPM1 mutations and adverse-risk cytogenetics among 2426 patients. The authors demonstrate that outcomes for cytogenetic adverse-risk AML are not modulated by the presence or absence of NPM1 mutations, thereby clarifying management for patients.
Topics & Concepts
NPM1CytogeneticsMedicineMyeloid leukemiaNucleophosminInternal medicineOncologyGene mutationAdverse effectKaryotypeCancer researchMutationGeneticsGeneBiologyChromosomeAcute Myeloid Leukemia ResearchNeutrophil, Myeloperoxidase and Oxidative MechanismsAdvanced biosensing and bioanalysis techniques